Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy

Universitaire Ziekenhuizen KU Leuven

Status: Completed

Conditions: Allergic Rhinitis

Study type: Observational

Funder types: Other

Identifiers

NCT01777438

102012

Details and patient eligibility

About

Allergic rhinitis (AR) is defined as inflammation of the nasal mucosa after exposition to an allergen in sensitized patients. AR causes not only nasal symptoms such as sneezing, itchy nose, rhinorrhea and nasal obstruction, but also has a significant impact on quality of life. Symptom control and overall satisfaction in patients undergoing subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) on the long term has not yet been investigated so far.

Enrollment: 434 patients

Sex: All

Ages: 19 to 59 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients with at least 2 AR symptoms and a positive skin prick test for the 20 most prevalent inhalant allergens (house dust mites, grass pollen, tree pollen, animal dander, Alternaria, Penicillium and Cladosporium) in Belgium.
2. Moderate/severe and/or persistent AR according to ARIA guidelines
3. Age > 18 and < 60 years.
4. Written informed consent
5. Dutch, French or English speaking patients

Exclusion criteria

Exclusion criteria

1. Age < 18 and > 60 years
2. Patients with mild AR
3. Patients not being able to give an informed consent
4. Patients being enrolled in other clinical trials
5. No knowledge of Dutch, French or English

Trial design

434 participants in 2 patient groups

control group

Description:

a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period

patients having SCIT

Description:

patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.